Report Highlights

U.S. Allergy Immunotherapy Market: Market Overview

The U.S. allergy immunotherapy market is the largest single-country segment globally, accounting for roughly 38% of worldwide immunotherapy revenues in 2024. The market is structurally bifurcated between subcutaneous immunotherapy (SCIT), administered in allergist offices as a reimbursed clinical procedure, and sublingual immunotherapy (SLIT), delivered via FDA-approved tablets such as Odactra, Grastek, Ragwitek, and Palforzia. This dual-channel structure creates distinct competitive dynamics: SCIT revenues are clinic-captive and relatively inelastic, while SLIT revenues follow retail pharmacy and specialty pharmacy distribution models with entirely different payer negotiation logic.

The U.S. market differs from European counterparts in two structural ways. First, the FDA regulates allergy extracts under biologics license authorities, meaning compounded SCIT mixes used widely in U.S. allergist offices operate under a long-standing regulatory exemption rather than full product approval—a grey zone that creates both incumbency protection and regulatory risk. Second, commercial payer coverage, not national health system reimbursement, governs access. With over 170 million Americans covered by private insurance, formulary positioning by the top five pharmacy benefit managers determines effective market reach more decisively than clinical evidence alone.

Growth Drivers in the U.S. Allergy Immunotherapy Market

The primary demand driver is the measurable increase in allergic disease prevalence across the U.S. population. CDC data confirms that 81 million Americans were diagnosed with seasonal allergic rhinitis in 2023, up from 67 million in 2015. Aeroallergen sensitization is rising in parallel with urban heat island effects and extended pollen seasons—a trend documented in a 2023 NEJM study linking climate-driven pollen intensification to a 21% increase in airborne allergen load in northeastern metropolitan areas since 2000. This epidemiological pressure translates directly into volume growth for immunotherapy regardless of product type.

Two additional structural drivers sustain growth. The FDA's approval of Palforzia (peanut oral immunotherapy, Aimmune Therapeutics) in January 2020 opened a food allergy segment previously unaddressed by immunotherapy, with pediatric allergist adoption accelerating sharply after Blue Cross Blue Shield national coverage determination in 2022. Simultaneously, the American Academy of Allergy, Asthma and Immunology's updated 2023 practice parameters formally recommended SLIT tablets as first-line options for specific allergen groups—a guideline shift that is already driving primary care prescribing volume independent of specialist referrals, broadening the effective prescriber base by an estimated 40,000 U.S. physicians.

Market Restraints and Entry Barriers

The most significant structural barrier in the U.S. allergy immunotherapy market is the biologics licensing pathway under 21 CFR Part 610, which governs allergy extracts. New entrants seeking FDA approval for subcutaneous allergen extracts face a pathway without a defined product approval precedent—most U.S. SCIT formulations rely on the Biologics License Application exemption for compounded allergen extracts, a regulatory status that the FDA has repeatedly signaled it intends to reform but has not yet acted upon. Any regulatory clarification forcing standardized extract approval would impose hundreds of millions of dollars in clinical trial costs, effectively barring small manufacturers from the SCIT channel.

Distribution complexity compounds regulatory barriers. The SCIT channel is controlled by approximately 5,200 U.S. board-certified allergists who compound and administer patient-specific extract mixtures in-office. These physicians collectively represent both the prescribers and the service delivery nodes, creating a captive economic structure that resists external disruption. Allergy extract suppliers—including Greer, ALK-Abelló, and Jubilant HollisterStier—have decade-long relationships and logistics arrangements embedded in allergist practice management systems. For the SLIT tablet segment, the barrier is pharmacy benefit manager formulary access: Tier 2 or Tier 3 placements on major PBM formularies impose patient cost-sharing above $100 per month, which clinical literature shows reduces adherence below therapeutic thresholds within six months of initiation.

Market Opportunities in the U.S. Allergy Immunotherapy Market

The most immediate near-term opportunity lies in the food allergy immunotherapy segment, which remains commercially underpenetrated. Palforzia achieved only 12,000 active patients in 2023 despite an estimated 1.6 million children with clinical peanut allergy in the U.S. meeting eligibility criteria—a penetration rate below 1%. DBV Technologies' Viaskin Peanut patch technology, if approved following its re-submitted BLA, would create an epicutaneous immunotherapy category in food allergy with an addressable market exceeding USD 800 million by 2028 at standard specialty pricing. Investors and strategic partners should evaluate early licensing positions in epicutaneous and oral food immunotherapy platforms before a second approval catalyzes payer coverage standardization.

A second high-value opportunity is the digitally-integrated home immunotherapy model. Telehealth-enabled SCIT supervision—where patients receive injections at retail clinics or home settings with allergist remote oversight—is being piloted by companies including Curex and Wyndly. This model targets the approximately 60% of U.S. allergy sufferers who never reach an allergist due to access or cost barriers. Curex reported 300% year-over-year patient growth in 2023 using physician-supervised at-home SLIT drops, a segment that sits outside current FDA-approved SLIT tablet frameworks but commands strong consumer demand and premium direct-to-consumer pricing, with monthly revenues per patient averaging USD 90–120 outside insurance channels.

Market at a Glance

Leading Market Participants

• ALK-Abelló
• Greer Laboratories
• Stallergenes Greer
• Jubilant HollisterStier
• Aimmune Therapeutics (Nestlé Health Science)
• DBV Technologies
• Allergy Therapeutics
• Circassia Pharmaceuticals
• Curex
• Wyndly Health

Regulatory and Policy Environment

Allergy immunotherapy in the U.S. is regulated primarily under the Public Health Service Act Section 351, with the FDA's Center for Biologics Evaluation and Research (CBER) holding jurisdiction over both allergen extracts and SLIT tablets. Approved SLIT products—Grastek (timothy grass, ALK-Abelló, approved 2014), Odactra (house dust mite, ALK-Abelló, approved 2017), Ragwitek (short ragweed, ALK-Abelló, approved 2014), and Palforzia (peanut, Aimmune, approved 2020)—each carry specific Risk Evaluation and Mitigation Strategy (REMS) programs requiring certified prescribers and first-dose in-office administration. SLIT drops remain unapproved by the FDA, occupying a legally ambiguous off-label space that the agency's 2022 draft guidance on compounded biologics flagged as an area of pending enforcement clarification.

Medicare Part B reimburses SCIT under CPT codes 95115–95117, with 2024 national average payment rates of approximately USD 18 per injection visit, while Medicare Part D governs SLIT tablet reimbursement under pharmacy benefit rules. The Inflation Reduction Act of 2022 does not yet directly affect allergy immunotherapy pricing, but its drug price negotiation framework creates downstream PBM behavior that will influence specialty immunotherapy formulary positioning by 2027. CMS finalized an expanded telehealth coverage policy in 2024 that includes allergy management services, a policy likely to accelerate telehealth-based immunotherapy supervision models and reshape geographic access economics substantially before 2028.

Long-Term Outlook for U.S. Allergy Immunotherapy

By 2032, the U.S. allergy immunotherapy market is structurally expected to shift from allergist-office-centric SCIT delivery toward a multi-channel model in which SLIT tablets and digitally-supervised home protocols collectively represent over 45% of treatment volume. Pipeline molecules—including biologics-adjuvanted immunotherapy combinations under investigation at Stanford's Sean N. Parker Center and IL-4Rα-targeted combination protocols in Phase II trials—will not reach commercial scale within the forecast period but will establish a clinical narrative that sustains premium pricing for the category as a disease-modifying intervention rather than symptomatic management.

The competitive landscape by 2032 will consolidate around three to four integrated immunotherapy platforms that control both the diagnostic sensitization testing and the therapeutic delivery infrastructure. ALK-Abelló's acquisition strategy and Nestlé Health Science's ownership of Aimmune position both entities to dominate the food allergy sub-segment, while telehealth-native companies will capture a meaningful share of aeroallergen SLIT volume if FDA guidance formalizes at-home administration pathways. Payer pressure on SCIT procedure reimbursement will likely compress allergist margins, incentivizing practice consolidation into allergy specialty networks—a structural shift that will create acquisition opportunities for private equity-backed rollup platforms targeting the 5,200 U.S. allergist practices currently operating independently.